Claims for Patent: 9,248,200

Summary for Patent: 9,248,200

Title:	Method of delivering an anti-cancer agent to a cell
Abstract:	There is provided a delivery vehicle comprising an anti-cancer agent together with a conjugate of a delivery agent containing a free aldehyde and a flavonoid, having the delivery agent conjugated at the C6 and/or the C8 position of the A ring of the flavonoid. The resulting delivery vehicles may be used to deliver an anti-cancer agent to a cell.
Inventor(s):	Ying; Jackie Y. (Singapore, SG), Chung; Joo Eun (Singapore, SG), Kurisawa; Motoichi (Singapore, SG)
Assignee:	Agency for Science, Technology and Research (Singapore, SG)
Application Number:	12/739,668
Patent Claims:	1. A micellar nanocomplex comprising: trastuzumab; and a conjugate of: (i) aldehyde-terminated polyethylene glycol; and (ii) a flavonoid that is either monomeric (-)-epigallocatechin gallate or oligomeric (-)-epigallocatechin gallate, the micellar nanocomplex having the polethylene glycol conjugated at the C6 and/or the C8 position of the A ring of the flavonoid by attachment of the polyethylene glycol via reaction of the free aldehyde group with the C6 and/or C8 position of the A ring of the flavonoid, and exhibiting an anti-cancer effect on a cell as a result of a synergistic effect between the anti-cancer effect of the trastuzumab and the anti-cancer effect of the flavonoid, wherein when the flavonoid is monomeric (-)-epigallocatechin gallate, the micellar nanocomplex further comprises non-conjugated oligomeric (-)-epigallocatechin gallate in an inner core of the micellar nanocomplex, wherein the trastuzumab is complexed with either the conjugated or non-conjugated oligomeric (-)-epigallocatechin gallate, whichever is present. 2. The micellar nanocomplex of claim 1 wherein the aldehyde-terminated polyethylene glycol is conjugated to oligomeric (-)-epigallocatechin gallate. 3. The micellar nanocomplex of claim 2, wherein the oligomeric (-)-epigallocatechin gallate is formed from (-)-epigallocatechin gallate monomers that have been oligomerized through enzyme-catalyzed oxidative coupling. 4. The micellar nanocomplex of claim 2, wherein the oligomeric (-)-epigallocatechin gallate is formed from (-)-epigallocatechin gallate monomers that have been oligomerized through aldehyde-mediated oligomerization. 5. The micellar nanocomplex of claim 2, wherein the oligomeric (-)-epigallocatechin gallate is formed from (-)-epigallocatechin gallate monomers that have been oligomerized through a carbon-carbon linkage between the C6 or C8 position on the A ring of a first monomeric unit to the C6 or C8 position on the A ring of a second monomeric unit. 6. The micellar nanocomplex of claim 1 wherein the aldehyde-terminated polyethylene glycol is conjugated to monomeric (-)-epigallocatechin gallate and the micellar nanocomplex comprises an inner core containing non-conjugated oligomeric (-)-epigallocatechin gallate. 7. The micellar nanocomplex of claim 6, wherein the oligomeric (-)-epigallocatechin gallate is formed from (-)-epigallocatechin gallate monomers that have been oligomerized through enzyme-catalyzed oxidative coupling. 8. The micellar nanocomplex of claim 6, wherein the oligomeric (-)-epigallocatechin gallate is formed from (-)-epigallocatechin gallate monomers that have been oligomerized through aldehyde-mediated oligomerization. 9. The micellar nanocomplex of claim 6, wherein the oligomeric (-)-epigallocatechin gallate is formed from (-)-epigallocatechin gallate monomers that have been oligomerized through a carbon-carbon linkage between the C6 or C8 position on the A ring of a first monomeric unit to the C6 or C8 position on the A ring of a second monomeric unit. 10. A pharmaceutical composition comprising the micellar nanocomplex according to claim 1. 11. A pharmaceutical composition comprising the micellar nanocomplex according to claim 2. 12. A pharmaceutical composition comprising the micellar nanocomplex according to claim 6. 13. A method of delivering trastuzumab to a cell comprising contacting the micellar nanocomplex of claim 1 with the cell. 14. The method according to claim 13, wherein the cell is in vitro. 15. The method according to claim 13, wherein the cell is in vivo and the method comprises administering the micellar nanocomplex to a subject in need of anti-cancer treatment.

Details for Patent 9,248,200

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Genentech, Inc.	HERCEPTIN	trastuzumab	For Injection	103792	09/25/1998		2027-10-23
Genentech, Inc.	HERCEPTIN	trastuzumab	For Injection	103792	02/10/2017		2027-10-23
Genentech, Inc.	HERCEPTIN HYLECTA	trastuzumab and hyaluronidase-oysk	Injection	761106	02/28/2019		2027-10-23